Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LPHAIC for ICC: HAIC + Lenvatinib + Tislelizumab in Advanced Intrahepatic Cholangiocarcinoma
NCT07646717Phase 2Active, not recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Feb 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of irinotecan liposome, fluorouracil, folinic acid, lenvatinib and tislelizumab in intrahepatic cholangiocarcinoma (ICC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Objective Response Rate. Started Feb 2026; status: active, not recruiting.
02
Drugs
irinotecan liposomefluorouracilfolinic acidlenvatinibtislelizumab
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT07646717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07646717.